Global Neurology Clinical Trials Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends 2026-2030

The neurology clinical trials market comprises the infrastructure, contract research organizations, technology platforms, and professional services dedicated to developing treatments for conditions affecting the brain, spinal cord, and peripheral nerves. This segment of the broader clinical research industry has grown substantially as neurological disorders have become one of the largest contributors to global disease burden, with conditions such as dementia, epilepsy, and movement disorders affecting hundreds of millions of people worldwide.

• •Market valued at approximately $5.84 billion in 2024, reaching $6.21 billion in 2025
• •Projects to grow through 2030 at a compound annual growth rate of 6.39%
• •Encompasses Phase I-IV trials across a wide range of neurological indications

The primary catalyst for market expansion is the increasing global incidence of neurological disorders, driven by aging demographics and lifestyle-related conditions. Additionally, advances in neuroscience research, biomarker development, and precision medicine approaches have renewed pharmaceutical interest in CNS drug development after a period of high failure rates.

• •Rising prevalence of neurodegenerative diseases among aging populations
• •Improved understanding of neurological pathophysiology enabling targeted therapeutic development
• •Increased regulatory incentives and orphan drug designations for rare neurological conditions

The market is commonly segmented by trial phase (Phase I, II, III, and IV), study design (interventional versus observational), and specific neurological indications including Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, migraine, and stroke. Geographically, North America historically dominates due to advanced research infrastructure and regulatory frameworks, while Europe and Asia-Pacific represent significant and growing markets.

• •Phase III trials represent the largest segment due to high costs and patient enrollment requirements
• •North America leads in market share, with Asia-Pacific emerging as the fastest-growing region
• •Academic medical centers and specialized neurology clinics serve as primary trial sites

What are the recent trends and outlook?

Emerging trends include the adoption of digital health technologies, artificial intelligence for patient stratification and endpoint measurement, and decentralized trial models that reduce geographic barriers to participation. The market faces challenges including high trial failure rates in neurology, lengthy development timelines, and complex regulatory requirements, but these are being addressed through adaptive trial designs and improved surrogate endpoints.

• •Growing use of digital biomarkers and wearable devices for remote patient monitoring
• •Expansion of academic-industry partnerships to access specialized patient populations
• •Anticipated pipeline maturation as several high-profile Alzheimer's and Parkinson's therapies approach regulatory decisions